Table 3 Occurrence of fistula and perforation according to bevacizumab administration
C (n = 75) | BC (n = 144) | RR (95% CI) | P value | |
|---|---|---|---|---|
GI fistula | ||||
Grade 2 | 0 | 1 (0.5) | NA | > 0.999 |
Grade 3 | 2 (0.9) | 5 (2.3) | 1.313 (0.249–6.934) | 0.748 |
Grade 4 | 0 | 3 (1.4) | NA | 0.999 |
GU fistula | ||||
Grade 2 | 0 | 1 (0.5) | NA | > 0.999 |
Grade 3 | 1 (0.5) | 5 (2.3) | 2.662 (0.305–23.208) | 0.376 |
Grade 4 | 0 | 1 (0.5) | NA | > 0.999 |
GI fistula & GU fistula | ||||
Grade 3 | 0 | 7 (3.2) | NA | 0.999 |
Grade 4 | 0 | 1 (0.5) | NA | > 0.999 |
GI perforation | ||||
Grade 3 | 2 (0.9) | 4 (1.8) | 1.043 (0.187–5.829) | 0.962 |
Grade 4 | 1 (0.5) | 2 (0.9) | 1.042 (0.093–11.684) | 0.973 |
Total | ||||
- | 6 (8.0) | 30 (20.8) | 3.026 (1.199–7.640) | 0.019 |